Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$47.49 +2.6%	$47.85	$39.35 ▼ $63.33	$94.20B	0.36	12.91 million shs	21.03 million shs
IOVA Iovance Biotherapeutics	$1.74 +1.2%	$2.24	$1.64 ▼ $12.51	$574.37M	0.85	9.02 million shs	9.30 million shs
MRK Merck & Co., Inc.	$81.75 +3.3%	$79.09	$73.31 ▼ $129.93	$198.77B	0.39	13.20 million shs	21.80 million shs
NVS Novartis	$123.06 +1.7%	$114.16	$96.06 ▼ $123.80	$255.62B	0.59	1.58 million shs	1.43 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.02%	-1.32%	-3.96%	-22.14%	+11.61%
IOVA Iovance Biotherapeutics	+1.78%	-7.03%	-1.83%	-47.08%	-78.55%
MRK Merck & Co., Inc.	+0.33%	-1.20%	+3.03%	-9.06%	-36.03%
NVS Novartis	+0.65%	+2.99%	+4.68%	+10.58%	+13.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.9226 of 5 stars	3.2	3.0	4.2	4.0	3.4	3.3	1.3
IOVA Iovance Biotherapeutics	4.7006 of 5 stars	4.3	1.0	0.0	4.2	1.8	4.2	1.3
MRK Merck & Co., Inc.	4.9963 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
NVS Novartis	1.6345 of 5 stars	1.0	3.0	2.5	0.0	2.8	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$58.00	22.13% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	602.43% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	33.56% Upside
NVS Novartis	2.00	Hold	$123.38	0.26% Upside

Current Analyst Ratings Breakdown

Latest IOVA, NVS, BMY, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	2.00	$6.04 per share	7.86	$8.08 per share	5.88
IOVA Iovance Biotherapeutics	$164.07M	3.54	N/A	N/A	$2.33 per share	0.75
MRK Merck & Co., Inc.	$64.17B	3.20	$9.78 per share	8.36	$18.33 per share	4.46
NVS Novartis	$50.32B	5.17	$10.88 per share	11.31	$21.59 per share	5.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.79	7.80	1.37	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.90	8.26	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	19.23	13.97	1.74	24.70%	39.44%	16.43%	7/17/2025 (Estimated)

Latest IOVA, NVS, BMY, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.22%	N/A	92.88%	17 Years
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	3.96%	N/A	47.16%	14 Years
NVS Novartis	$2.60	2.11%	N/A	40.63%	N/A

Latest IOVA, NVS, BMY, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVS Novartis	0.56	0.79	0.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
IOVA Iovance Biotherapeutics	77.03%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.07%
IOVA Iovance Biotherapeutics	10.30%
MRK Merck & Co., Inc.	0.09%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable

IOVA, NVS, BMY, and MRK Headlines

Recent News About These Companies

ProFound Therapeutics Inks $750M+ Deal with Novartis

5 hours ago | contractpharma.comC

Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?

July 1 at 10:15 AM | zacks.com

Novartis: Strong Growth and Product Performance Amid Valuation Concerns and Generic Competition Risks

July 1 at 6:42 AM | tipranks.com

EXCLUSIVE: Vamos Racquets brings padel, pickleball to former Novartis campus (updated)

June 30 at 11:52 PM | njbiz.comN

Novartis (NYSE:NVS) Sets New 52-Week High - Time to Buy?

June 30 at 2:50 PM | marketbeat.com

Altus Wealth Group LLC Purchases New Stake in Novartis AG (NYSE:NVS)

June 30 at 9:03 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Sold by First Fiduciary Investment Counsel Inc.

June 30 at 8:34 AM | marketbeat.com

Novartis AG (NYSE:NVS) Stake Boosted by Joel Isaacson & Co. LLC

June 30 at 5:21 AM | marketbeat.com

7 Killer European Stocks To Buy In July

June 29 at 10:52 AM | 247wallst.com

4,702 Shares in Novartis AG (NYSE:NVS) Bought by Guerra Advisors Inc

June 29 at 7:39 AM | marketbeat.com

BSW Wealth Partners Has $401,000 Stock Holdings in Novartis AG (NYSE:NVS)

June 29 at 5:13 AM | marketbeat.com

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

June 28 at 12:45 PM | insidermonkey.com

Mirae Asset Global Investments Co. Ltd. Has $47.87 Million Holdings in Novartis AG (NYSE:NVS)

June 28 at 5:43 AM | marketbeat.com

Sequoia Financial Advisors LLC Has $3.65 Million Stake in Novartis AG (NYSE:NVS)

June 28 at 4:27 AM | marketbeat.com

What is Zacks Research's Forecast for Novartis Q1 Earnings?

June 28 at 2:24 AM | americanbankingnews.com

Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

June 27, 2025 | pmlive.comP

Bartlett & CO. Wealth Management LLC Has $9.84 Million Holdings in Novartis AG (NYSE:NVS)

June 27, 2025 | marketbeat.com

Q2 Earnings Estimate for Novartis Issued By Zacks Research

June 27, 2025 | marketbeat.com

Novartis AG (NYSE:NVS) Shares Sold by Cambridge Investment Research Advisors Inc.

June 27, 2025 | marketbeat.com

Novartis, ProFound Therapeutics Ink Multi-Year Collaboration to Target Cardiovascular Disease Proteins

June 27, 2025 | genengnews.comG

Novartis and Cannes Can: Diversity Collective Team Up To Address Racial Health Disparities

June 26, 2025 | blackenterprise.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

IOVA, NVS, BMY, and MRK Company Descriptions

Bristol Myers Squibb NYSE:BMY

$47.49 +1.20 (+2.59%)

Closing price 03:59 PM Eastern

Extended Trading

$47.78 +0.29 (+0.62%)

As of 07:55 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Iovance Biotherapeutics NASDAQ:IOVA

$1.74 +0.02 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 0.00 (0.00%)

As of 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Merck & Co., Inc. NYSE:MRK

$81.75 +2.59 (+3.27%)

Closing price 03:59 PM Eastern

Extended Trading

$82.02 +0.27 (+0.33%)

As of 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$123.06 +2.05 (+1.69%)

Closing price 03:59 PM Eastern

Extended Trading

$123.11 +0.05 (+0.04%)

As of 07:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time